April 21, 2026 10:24 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
15 killed, 20 injured as bus plunges into gorge in J&K’s Udhampur | Oil jumps over 5% as Strait of Hormuz closure fuels supply fears | Pushback from smartphone makers: Centre drops Aadhaar app pre-install plan — report | Meta eyes first wave of layoffs on May 20: Report | TCS breaks silence on Nida Khan: ‘No HR role, no power’ in Nashik case | ‘Panic reaction’: Rahul Gandhi on women’s bill, says PM Modi ‘wants to send a message’ | Adani Group shares rise as Gautam Adani becomes Asia’s richest, overtakes Mukesh Ambani | TCS Nashik ‘conversion’ case accused seeks anticipatory bail citing pregnancy | IT raids TMC candidate Debasish Kumar’s premises ahead of Bengal polls | Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote
Photo courtesy: twitter.com/yogrishiramdev

SC issues contempt notice to Ramdev's Patanjali Ayurved, Acharya Balkrishna for misleading ads on medicines

| @indiablooms | Feb 28, 2024, at 04:16 am

New Delhi: The Supreme Court on Tuesday issued a show cause notice to Patanjali Ayurved and the company’s managing director Acharya Balkrishna for deviating from their promise to not make misleading claims in their product advertisements, media reports said.

The apex court put restrictions on the company co-founded by Yoga guru Baba Ramdev from circulating any advertisement with claims to cure illnesses such as high blood pressure, diabetes, fevers, epilepsy and lupus, which are mentioned in the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Moneycontrol reported.

The court slammed the company and criticised the government in strong words.

“The entire country is being taken for a ride" and the government is "sitting with its eyes closed," it said, according to the report.

Pulling up the government for lack of action, the court directed it to submit a sworn statement detailing measures implemented to curb companies' dissemination of inaccurate medication representations through the media.

Patanjali and its staff received a warning against disseminating any misleading claims regarding their product's capacity to treat illnesses.

This directive was issued in response to a writ petition filed by the Indian Medical Association (IMA) over misleading advertisements by certain companies.

In November, Patanjali had promised to refrain from publishing ads that made false claims about its products and disparaged modern medicines and vaccinations.

However, despite this commitment, Patanjali continued to run such advertisements, as reported to the court.

In November 2023, the court warned Patanjali and said, "All false and misleading advertisements by Patanjali Ayurved have to stop immediately. This court will take such infractions very seriously and will consider imposing costs of up to Rs 1 crore on every product for which a false claim is made that it can cure a particular disease."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.